AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02369718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to 12 Fournier's lists of words
Description: Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
Study NCT02369718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to 48 Fournier's lists of words
Description: 48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
Study NCT00744172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: laparoscopic hysterectomy
Study NCT00744172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal
Description: vaginal hysterectomy
Study NCT00744172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal
Description: abdominal hysterectomy
Study NCT01561794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: (1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.
Study NCT00332124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: 900 mg every day until birth of infant
Study NCT00332124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn oil every day in place of choline
Study NCT01199120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
Study NCT01071850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet
Study NCT01071850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral tablet
Study NCT01071850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6-mercaptopurine,Methotrexate
Description: 6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine
Description: Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate
Description: Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase
Description: Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase
Description: Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate, 6-mercaptopurine
Description: 6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
Study NCT02128776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive care medical home
Description: Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
Study NCT03961152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCoach app
Description: In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
Study NCT01229839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embolization
Description: embolization with lipiodol and polyvinyl alcohol particles (PVA)
Study NCT01229839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of anticancer agent
Description: infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
Study NCT01229839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of mixture of anticancer agent and lipiodol
Description: infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
Study NCT03987451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
Study NCT03987451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo s.c. given once-weekly for 48 weeks
Study NCT02128776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAM (Confusion Assesment Method)
Description: During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated.
Study NCT03538002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-light filtering spectacle lenses
Description: This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
Study NCT01802801 — intervention group
Intervention type: OTHER
Intervention: embryo development
Description: intra- and inter-observator analysis
Study NCT03113071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered in combination with Digoxin
Study NCT03113071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Decitabine will be administered in combination with Digoxin
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CATQUEST 9-SF
Description: The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6CIT
Description: This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
Study NCT00679666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: 01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
Study NCT00679666 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
Study NCT02568774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture
Description: Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
Study NCT02568774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
Study NCT01611155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: Given PO
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel Index
Description: To evaluate the everyday independence of the subject and it's trend durin the follow-up
Study NCT04047485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial Microscopy - Cornea
Description: Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
Study NCT01611155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01611155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01611155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01611155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01611155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02021773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 High Dose
Description: Subcutaneously Administered LBR-101 Monthly x 3
Study NCT02021773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 Low Dose
Description: Subcutaneously Administered LBR-101 Monthly x 3
Study NCT02021773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study NCT02903836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin 800 mg 3 days
Study NCT02903836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin 800 mg 5 days
Study NCT00517790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869 .25 mg/kg
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Study NCT00517790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869 0.10 mg/kg
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Study NCT04658485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
Study NCT04658485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
Study NCT01969214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-MM-101
Description: Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day
Study NCT00760552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Intervention
Description: High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
Study NCT00760552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Intervention
Description: Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
Study NCT00760552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All- 6 month pharmacist intervention
Description: All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
Study NCT01459627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Description: Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
Study NCT01459627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 months DAPT
Description: Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
Study NCT03107845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
Study NCT03107845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Feedback
Description: Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
Study NCT03107845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Feedback plus CST
Description: Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation.
Study NCT04512014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate
Description: perioperative measurement of lactate levels
Study NCT04352569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
Study NCT04352569 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
Study NCT02903836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Study NCT00500500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761® (Tanakan®)
Study NCT00500500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EGb 761® (Tanakan®)
Study NCT00756743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
Study NCT03626766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Verification Alert
Description: Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
Study NCT03626766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Banner
Description: Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
Study NCT03626766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photo in Banner and Verification Alert
Description: Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
Study NCT03808740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 0.5 mg/kg/day.
Study NCT03808740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study NCT04439188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-beta Inhibitor GSK2636771
Description: Given PO
Study NCT06353191 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT02119962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study NCT02119962 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study NCT04413032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMS
Description: The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.